21.07.2020 Biotest AG  DE0005227235

DGAP-News: Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020


 

DGAP-News: Biotest AG / Key word(s): Research Update
Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020

21.07.2020 / 07:00
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020

  • Biotest unveiled new data about its novel recombinant Factor VIII molecules
  • High bioavailability of 50% after subcutaneous (sc.) injection
  • Substantially decreased dosing frequency expected due to 4-fold half-life extension in animal models
  • Low immunogenicity and reduced risk of inhibitor development based on specific design expected
  • Biotest explores partnering options to accelerate the development program

Dreieich, 21 July 2020. Biotest unveiled functional data from its new Factor VIII compounds at the ISTH 2020 congress (International Society on Thrombosis and Haemostasis). The content of the oral presentation and three scientific posters on its innovative compounds HAT (Haemophilia A Therapeutic) and HAT RI (Haemophilia A Therapeutic Reduced Immunogenicity) is available at Biotests homepage:
https://www.biotest.com/de/en/r_d/our_research_focus/haematology.cfm

HAT and HAT RI address the three major challenges of current Factor VIII products for haemophilia A therapy, which are the short Factor VIII half-life, the intravenous application route and the high risk for inhibitor development.

The molecules demonstrate a great potential for subcutaneous administration, evidenced by a high bioavailability of 50% observed in the "Göttingen minipig model".

Results from further animal models support a 4-fold extension of the half-life in blood circulation while maintaining the wild-type characteristics of activated Factor VIII with full in vivo functionality. Thus, a substantially decreased administration frequency can be expected.

The specific design of HAT and HAT RI shall confer lowest immunogenicity and reduced risk of inhibitor development, which is further enhanced by specific de-immunizing modifications in the HAT RI variant.

Biotest is currently looking for a partner in order to accelerate further development.

About HAT
HAT and HAT RI (Haemophilia A Therapeutic and Haemophilia A Therapeutic Reduced Immunogenicity) are in preclinical development for the treatment of haemophilia A. HAT and HAT RI are characterized by a substantial half-life extension of Factor VIII and the potential for intravenous and subcutaneous administration. These benefits are based on the fusion of special Factor VIII sequences with four albumin-binding peptides shielding the active substance from degradation. HAT RI additionally provides modifications within the Factor VIII section to further reduce the risk of inhibitor development, one of the major issues in haemophilia A therapy.

About Haemophilia
As a lifelong inherited bleeding disorder, haemophilia affects about 1 in 10,000 people worldwide. People with haemophilia experience prolonged internal bleeding that can result from a seemingly minor injury. Bleeding into joints and muscles causes severe pain and disability while bleeding into major organs, such as the brain, can cause death. Treating the bleeding episodes involves the prompt and proper use of clotting factor concentrates. Haemophilia A is caused by a deficiency of clotting factor VIII. A treatment option is the intravenously replacement of the missing factor. Therapy intervals may vary from patient to patient, but can require replacement several times a week, making haemophilia therapy quite burdensome. Up to 30% of patients with severe haemophilia develop antibodies (inhibitors) against the therapeutic factor VIII. The formation of inhibitors is the most serious complication of today's haemophilia treatment. For more information on haemophilia and FVIII, please visit the World Federation of Haemophilia website at https://www.wfh.org/en/home.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Business development contact
Dr Dagmar Wolff
Mail: business-development@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



21.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1097773

 
End of News DGAP News Service

1097773  21.07.2020 

fncls.ssp?fn=show_t_gif&application_id=1097773&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 500,80 582,00 589,60 553,10 378,10 400,30 419,10 460,00
EBITDA1,2 85,60 85,90 22,40 86,60 13,00 35,20 30,50 23,50
EBITDA-Marge3 17,09 14,76 3,80 15,66 3,44 8,79 7,28 5,11
EBIT1,4 53,80 53,40 -71,80 63,90 -9,30 10,60 -1,20 -7,50
EBIT-Marge5 10,74 9,18 -12,18 11,55 -2,46 2,65 -0,29 -1,63
Jahresüberschuss1 32,00 19,20 -82,50 -45,70 -3,50 181,70 -4,70 -8,00
Netto-Marge6 6,39 3,30 -13,99 -8,26 -0,93 45,39 -1,12 -1,74
Cashflow1,7 -7,20 -11,40 38,10 65,90 34,30 -50,00 -33,60 0,00
Ergebnis je Aktie8 0,75 0,50 -2,08 -1,17 -0,40 4,58 -0,11 -0,20
Dividende8 0,21 0,22 0,04 0,07 0,04 0,04 0,04 0,04
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

INVESTOR-INFORMATIONEN
©boersengefluester.de
Biotest VZ
WKN Kurs in € Einschätzung Börsenwert in Mio. €
522723 26,400 Halten 1.036,77
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 21,82 0,000 83,81
KBV KCV KUV EV/EBITDA
2,19 - 2,47 48,472
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
0,04 0,04 0,15 08.05.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2020 13.08.2020 12.11.2020 30.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
3,27% 19,66% 28,78% 21,10%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Biotest AG  ISIN: DE0005227235 können Sie bei DGAP abrufen

Gesundheit , 522723 , BIO3 , XETR:BIO3